肝细胞癌作为比较常见的一种恶性肿瘤,其致死率非常高,目前大部分肝细胞癌患者到院就诊时已经处于中晚期,可进行手术治疗的病例非常少,预后效果不理想。目前肝动脉化疗栓塞术在肝细胞癌的临床中已经得到了广泛应用,且所获疗效也得到了...肝细胞癌作为比较常见的一种恶性肿瘤,其致死率非常高,目前大部分肝细胞癌患者到院就诊时已经处于中晚期,可进行手术治疗的病例非常少,预后效果不理想。目前肝动脉化疗栓塞术在肝细胞癌的临床中已经得到了广泛应用,且所获疗效也得到了认可。为进一步探讨分析加深对肝动脉化疗栓塞术的认识,本次研究就肝动脉化疗栓塞术联合治疗原发性肝癌的研究现状及进展进行综述,希望可为今后肝细胞癌患者治疗方案的明确提供可参考依据。Hepatocellular carcinoma (HCC) is a common malignant tumor, and its mortality rate is very high. At present, most patients with HCC are in the middle and late stages when they go to the hospital. There are very few cases of feasible surgical treatment, and the prognosis is not ideal. At present, transcatheter arterial chemoembolization has been widely used in the clinical treatment of hepatocellular carcinoma, and its efficacy has also been recognized. In order to further explore and deepen the understanding of transcatheter arterial chemoembolization, this study reviewed the research status and progress of transcatheter arterial chemoembolization in the treatment of primary liver cancer, hoping to provide a reference for the future treatment of patients with hepatocellular carcinoma.展开更多
文摘肝细胞癌作为比较常见的一种恶性肿瘤,其致死率非常高,目前大部分肝细胞癌患者到院就诊时已经处于中晚期,可进行手术治疗的病例非常少,预后效果不理想。目前肝动脉化疗栓塞术在肝细胞癌的临床中已经得到了广泛应用,且所获疗效也得到了认可。为进一步探讨分析加深对肝动脉化疗栓塞术的认识,本次研究就肝动脉化疗栓塞术联合治疗原发性肝癌的研究现状及进展进行综述,希望可为今后肝细胞癌患者治疗方案的明确提供可参考依据。Hepatocellular carcinoma (HCC) is a common malignant tumor, and its mortality rate is very high. At present, most patients with HCC are in the middle and late stages when they go to the hospital. There are very few cases of feasible surgical treatment, and the prognosis is not ideal. At present, transcatheter arterial chemoembolization has been widely used in the clinical treatment of hepatocellular carcinoma, and its efficacy has also been recognized. In order to further explore and deepen the understanding of transcatheter arterial chemoembolization, this study reviewed the research status and progress of transcatheter arterial chemoembolization in the treatment of primary liver cancer, hoping to provide a reference for the future treatment of patients with hepatocellular carcinoma.
